Zobrazeno 1 - 10
of 465
pro vyhledávání: '"Houry, S."'
Autor:
Deniaud-Alexandre, E., Touboul, E., Tiret, E., Sezeur, A., Hannoun, L., Houry, S., Huguet, F., Pène, F., Parc, R., Schlienger, M.
Publikováno v:
In Cancer / Radiothérapie 2006 10(8):572-582
Autor:
André, T. *, Tournigand, C., Rosmorduc, O., Provent, S., Maindrault-Goebel, F., Avenin, D., Selle, F., Paye, F., Hannoun, L., Houry, S., Gayet, B., Lotz, J.P., de Gramont, A., Louvet, C.
Publikováno v:
In Annals of Oncology September 2004 15(9):1339-1343
Autor:
Deniaud-Alexandre, E, Touboul, E *, Tiret, E, Sezeur, A, Houry, S, Gallot, D, Parc, R, Huang, R, Qu, S.H, Pène, F, Schlienger, M
Publikováno v:
In Cancer / Radiothérapie 2003 7(4):237-253
Publikováno v:
In Annales de chirurgie 2003 128(6):359-363
Autor:
Pierre Laurent-Puig, M.P. Gaub, Gérard Milano, Daniel Benchimol, M.-C. Etienne-Grimaldi, Denis Pezet, Thierry André, A. B. P. Van Kuilenburg, Raoul C.M. Hennekam, Houry S, Raymon Vijzelaar, François-Noël Gilly, A. Mahamat, Sylviane Olschwang, A. Abderrahim-Ferkoune, B. Pradere, J.-L. Faucheron, C. Letoublon, Judith Meijer
Publikováno v:
pharmacogenomics journal, 15(3), 211-218. Nature Publishing Group
Dihydropyrimidine dehydrogenase is a crucial enzyme for the degradation of 5-fluorouracil (5FU). DPYD, which encodes dihydropyrimidine dehydrogenase, is prone to acquire genomic rearrangements because of the presence of an intragenic fragile site FRA
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0280058f7d1857cda47e387d5aa27e5c
https://doi.org/10.1038/tpj.2014.68
https://doi.org/10.1038/tpj.2014.68
Publikováno v:
In Annales de chirurgie 2001 126(7):618-628
Autor:
Virginie Huchet, Houry S, Philippe Rougier, Philippe Bouchard, Jean-Didier Grangé, Khaldoun Kerrou, Philippe Ruszniewski, Valérie Nataf, Françoise Duron, Françoise Montravers, Jean-Pierre Lotz, Jean-Noël Talbot
Publikováno v:
The Journal of Clinical Endocrinology & Metabolism. 94:1295-1301
Fluorodihydroxyphenylalanine-(18F) (FDOPA) positron emission tomography (PET) is a recent imaging modality used to localize endocrine tumors. This study was conducted to evaluate the impact of FDOPA-PET on the management of patients referred for carc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::348fbe8b17f84bccd67951903eaf6908
https://doi.org/10.1210/jc.2008-1349
https://doi.org/10.1210/jc.2008-1349
Autor:
Emmanuel Touboul, Philippe Ruszniewski, Khaldoun Kerrou, Dany Grahek, Jean-Didier Grangé, Fabrice Gutman, Françoise Montravers, Philippe Rougier, Houry S, Raoul Poupon, Thierry André, Jean-Noël Talbot, Olivier Rosmorduc, Virginie Huchet
Publikováno v:
La Presse Médicale. 37:e1-e24
In digestive oncology, the most frequent indication for FDG PET, in our experience and as reported in the literature, is the localisation of recurrent colorectal cancer. This molecular imaging method has also been shown to be clinically useful in var
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::be0b90aedf0d7fe9772539e1310a051b
https://doi.org/10.1016/j.lpm.2007.03.048
https://doi.org/10.1016/j.lpm.2007.03.048
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Houry S, C. Louvet, F. Maindrault-Goebel, François Paye, Brice Gayet, A. de Gramont, Olivier Rosmorduc, D. Avenin, Frédéric Selle, Laurent Hannoun, Christophe Tournigand, S. Provent, Thierry André, J. P. Lotz
Publikováno v:
Annals of Oncology. 15:1339-1343
Since gemcitabine-oxaliplatin (GEMOX) has been used in pancreatic adenocarcinoma, we studied its activity and tolerability in advanced biliary tract adenocarcinoma (ABTA).Consecutive adult patients with confirmed ABTA were recruited from four centers
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::82665d4acae725e6f4875cde5d26f32e
https://doi.org/10.1093/annonc/mdh351
https://doi.org/10.1093/annonc/mdh351